The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

Myasthenia gravis is a chronic condition that causes muscles to tire and weaken easily. For example, if you have myasthenia gravis, you may notice that during a meal, your jaw muscles become tired ...

In this final part of a recent interview with Jonathan Strober, MD, UCSF Benioff Children's Hospital and phase 2/3 ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the acetylcholine receptor (AChR ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

antibodies. Specialized tests use electricity to stimulate muscles and measure the strength of muscle contraction. If you have myasthenia gravis, muscle strength will decrease predictably over the ...

The body's immune system mistakenly produces "autoantibodies," or antibodies that attack its own tissues and proteins. In the case of myasthenia gravis, the body produces autoantibodies that ...

The body's immune system mistakenly produces "autoantibodies," or antibodies that attack its own tissues and proteins. In the case of myasthenia gravis, the body produces autoantibodies that ...

Myasthenia gravis, or MG, is "a chronic autoimmune ... Blood tests are also often used to identify associated antibodies. "About 80% of patients with MG are positive" for the antibody behind ...

had clinically meaningful efficacy and a favorable safety profile among people with generalized myasthenia gravis (gMG), topline data from the MINT trial showed. The anti-CD19 monoclonal antibody ...